| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 06/01/2025 | 14:32 | Business Wire | ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 | NASDAQ:CDXC | ChromaDex Corporation |
| 16/12/2024 | 22:00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CDXC | ChromaDex Corporation |
| 14/12/2024 | 01:12 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CDXC | ChromaDex Corporation |
| 13/12/2024 | 19:54 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CDXC | ChromaDex Corporation |
| 03/12/2024 | 14:34 | Business Wire | ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category | NASDAQ:CDXC | ChromaDex Corporation |
| 21/11/2024 | 23:20 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] | NASDAQ:CDXC | ChromaDex Corporation |
| 14/11/2024 | 14:32 | Business Wire | ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement | NASDAQ:CDXC | ChromaDex Corporation |
| 08/11/2024 | 22:47 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:CDXC | ChromaDex Corporation |
| 07/11/2024 | 14:32 | Business Wire | ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide | NASDAQ:CDXC | ChromaDex Corporation |
| 31/10/2024 | 21:04 | Business Wire | ChromaDex Corporation Reports Third Quarter 2024 Financial Results | NASDAQ:CDXC | ChromaDex Corporation |
| 31/10/2024 | 21:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:CDXC | ChromaDex Corporation |
| 28/10/2024 | 13:32 | Business Wire | ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024 | NASDAQ:CDXC | ChromaDex Corporation |
| 23/10/2024 | 14:34 | Business Wire | ChromaDex to Participate in the 17th Annual LD Micro Main Event | NASDAQ:CDXC | ChromaDex Corporation |
| 15/10/2024 | 14:32 | Business Wire | Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) | NASDAQ:CDXC | ChromaDex Corporation |
| 26/09/2024 | 22:12 | Business Wire | ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference | NASDAQ:CDXC | ChromaDex Corporation |
| 20/09/2024 | 14:32 | Business Wire | ChromaDex Appoints Ozan Pamir as Chief Financial Officer | NASDAQ:CDXC | ChromaDex Corporation |
| 10/09/2024 | 14:32 | Business Wire | ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics | NASDAQ:CDXC | ChromaDex Corporation |
| 09/09/2024 | 14:34 | Business Wire | ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions | NASDAQ:CDXC | ChromaDex Corporation |
| 23/08/2024 | 14:34 | Business Wire | ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024 | NASDAQ:CDXC | ChromaDex Corporation |
| 21/08/2024 | 12:06 | Edgar (US Regulatory) | Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] | NASDAQ:CDXC | ChromaDex Corporation |
| 19/08/2024 | 14:32 | Business Wire | ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+ | NASDAQ:CDXC | ChromaDex Corporation |
| 07/08/2024 | 22:04 | Business Wire | ChromaDex Corporation Reports Second Quarter 2024 Financial Results | NASDAQ:CDXC | ChromaDex Corporation |
| 05/08/2024 | 14:32 | Business Wire | ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference | NASDAQ:CDXC | ChromaDex Corporation |
| 24/07/2024 | 14:34 | Business Wire | ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024 | NASDAQ:CDXC | ChromaDex Corporation |
| 23/07/2024 | 14:32 | Business Wire | ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs) | NASDAQ:CDXC | ChromaDex Corporation |
| 22/07/2024 | 14:34 | Business Wire | ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel | NASDAQ:CDXC | ChromaDex Corporation |
| 16/07/2024 | 14:34 | Business Wire | ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August | NASDAQ:CDXC | ChromaDex Corporation |
| 01/07/2024 | 14:32 | Business Wire | ChromaDex to Join Russell 2000® Index | NASDAQ:CDXC | ChromaDex Corporation |
| 24/06/2024 | 14:32 | Business Wire | Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD) | NASDAQ:CDXC | ChromaDex Corporation |
| 13/06/2024 | 14:32 | Business Wire | ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC) | NASDAQ:CDXC | ChromaDex Corporation |